Vicapsys Life Sciences Inc does not currently pay dividends.
What is Vicapsys Life Sciences Inc’s EPS estimate?
Vicapsys Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vicapsys Life Sciences Inc have?
Vicapsys Life Sciences Inc has 31,915,741 shares outstanding.
What happened to Vicapsys Life Sciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vicapsys Life Sciences Inc?
Currently, no hedge funds are holding shares in VICP
---
Vicapsys Life Sciences Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.49%
Trailing 12-Months
This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. Its initial pipeline products include type 1 diabetes, post-surgical abdominal adhesion formation, and post-trauma keloid formation. The company was founded on December 26, 1996 and is headquartered in Cumming, GA.